Showing 1331-1340 of 5771 results for "".
- Alkeus Announces Interim TEASE-3 Study Results Evaluating Gildeuretinol in Early-Stage Stargardt Patientshttps://modernod.com/news/alkeus-announces-new-interim-tease-3-study-results-showing-gildeuretinol-prevented-disease-progression-in-early-stage-stargardt-patients/2482608/Alkeus Pharmaceuticals announced positive interim data from its TEASE-3 study demonstrating that additional early-stage Stargardt disease patients treated with oral gildeuretinol acetate showed no disease progression, including stable visual acuity, over multiple years. “Thes
- ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901; DSMB Approval to Advance Dose Escalation in Phase 1b RP Trialhttps://modernod.com/news/vigeneron-announces-fda-rare-pediatric-disease-designation-for-vg901-dsmb-approval-to-advance-dose-escalation-in-phase-1b-rp-trial/2482601/ViGeneron announced two important milestones for its novel gene therapy candidate VG901 to treat patients with retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. The FDA granted Rare Pediatric Disease Designation (RPD
- Oculis Announces Positive Phase 2 Results for OCS-05 in Acute Optic Neuritis as a Potential Neuroprotective Therapyhttps://modernod.com/news/oculis-announces-positive-phase-2-results-for-ocs-05-in-acute-optic-neuritis-as-a-potential-first-in-class-neuroprotective-therapy/2482597/Oculis announced positive topline results for OCS-05 in the phase 2 ACUITY trial for patients with acute optic neuritis. The trial met its primary endpoint of safety and achieved statistical significance on several key efficacy-based secondary endpoints. The phase 2 ACUIT
- VisionGift Announces the Retirement of Longtime Medical Director, Mark Terry, MDhttps://modernod.com/news/visiongift-announces-the-retirement-of-longtime-medical-director-mark-terry-md/2482595/VisionGift, a nonprofit dedicated ot ocular donation and corneal transplantation, announced the retirement of its medical director Mark Terry, MD, after 34 years of dedicated service to the field of eye banking. Succeeding him in this role will be Winston Chamberlain, MD, PhD, and
- National Eye Institute Study Revisits Role of Annexin-V Biomarker in Retinal Cell Degenerationhttps://modernod.com/news/national-eye-institute-study-revisits-role-of-annexin-v-biomarker-in-retinal-cell-degeneration/2482588/Recent findings from a National Eye Institute-led study shed new light on annexin-V, a widely used biomarker to track apoptosis and retinal cell death in eye disease. The study group identified that annexin-V also binds to immune cells, suggesting it may a have a role as a marker for ocular infla
- Aurion Announces Positive Topline Data for Phase 1/2 Trial of Allogeneic Cell Therapy for Corneal Edemahttps://modernod.com/news/aurion-announces-positive-topline-data-for-phase-12-trial-of-allogeneic-cell-therapy-for-corneal-edema-secondary-to-corneal-endothelial-dysfunction/2482584/Aurion Biotech announced topline data from its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy product candidate for the treatment of corneal edema secondary to corneal endothelial dysfunction. AURN001 is a combination cell therapy product candidate comprise
- Viridian Announces Topline Results from Veligrotug Phase 3 Trial in Patients with Chronic TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-veligrotug-phase-3-trial-in-patients-with-chronic-thyroid-eye-disease/2482580/Viridian Therapeutics announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED). “We are extremely
- Sepul Bio Announces First Patient Dosed in Trial Using Ultevursen for RPhttps://modernod.com/news/sepul-bio-annouces-dosage-of-first-participant-in-clinical-trial-using-ultevursen-for-retinitis-pigmentosa-treatment/2482578/Sepul Bio announced the first person has been dosed for the LUNA clinical study, a phase 2b trial using ultevursen for USH2A-associated retinitis pigmentosa (RP). USH2A, or Usher Syndrome type 2a, is the most common cause of autosomal recessive retinitis pigmentosa that affec
- ARPA-H Announces Pioneering Investments to Reverse Blindnesshttps://modernod.com/news/arpa-h-announces-pioneering-investments-to-reverse-blindness/2482572/The Advanced Research Projects Agency for Health (ARPA-H) announced the teams to receive the first investments from its Transplantation of Human Eye Allografts (THEA) program. ARPA-H, an agency w
- Nicox Announces First Commercial Sale of Zerviate in China by Partner Ocumensionhttps://modernod.com/news/nicox-announces-first-commercial-sale-of-zerviate-in-china-by-partner-ocumension/2482566/Nicox announced the first commercial sale of Zerviate (cetirizine ophthalmic solution), 0.24% in China by its exclusive Chinese partner Ocumension yesterday – a significant milestone in their longstanding collaboration since 2018. Zerviate is indicated for ocular itchin